Jun 16, 2025

Featuring perspectives from Dr Virginia F Borges, Ms Jamie Carroll, Mr Ronald Stein and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• Role of CDK4/6 Inhibitors in Localized and Metastatic Hormone Receptor (HR)-Positive Breast Cancer (12:49)
• PI3K Inhibition as First-Line Treatment for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (38:24)
• Clinical Utility of AKT and PI3K Inhibitors in Progressive HR-Positive mBC (1:01:44)
• Current and Future Role of Oral Selective Estrogen Receptor Degraders in HR-Positive mBC (1:24:38)

NCPD information and select publications